Polycystic ovary syndrome (PCOS) adversely affects metabolic health, reproductive hormones, and psychological well-being in affected women. This systematic review and meta-analysis aimed to evaluate the efficacy of mindfulness-based interventions (MBIs)—including yoga and mindfulness meditation—on anthropometric indices, metabolic profile, reproductive hormones, and quality of life in women with PCOS.
The review summarizes randomized controlled trial (RCT) evidence to determine whether MBIs can modify weight-related measures, insulin sensitivity, markers of hyperandrogenism, and psychological outcomes in this population.
The authors searched multiple databases including PubMed and the Cochrane Library through January 2025 to identify eligible RCTs. Ten randomized controlled trials met inclusion criteria, comprising a total of 356 participants. Data from the included trials were synthesized using Review Manager 5.3. Outcomes were reported as mean differences (MDs) or standardized mean differences (SMDs) depending on the measure.
Specifics of individual trial inclusion criteria, durations of interventions, and comparator conditions are reported in the full article; the abstract notes the pooled data and the analytic approach without listing all trial-level characteristics.
The pooled dataset consisted of 10 RCTs enrolling 356 women with PCOS. Interventions classified as MBIs in the review included programs such as yoga and mindfulness meditation. The abstract does not enumerate intervention frequency, session length, total duration, or detailed comparator descriptions; these details are available in the full text of the review.
Risk-of-bias assessments and heterogeneity metrics were conducted as part of the meta-analysis process, as implied by standard methodology, but specific risk-of-bias results and heterogeneity statistics are not presented in the abstract.
Pooled analyses showed significant reductions in BMI, body weight, and abdominal circumference for women randomized to MBIs compared with control groups. These findings indicate that MBIs may support weight management and central adiposity reduction in women with PCOS.
The review does not report exact effect sizes or confidence intervals in the abstract; readers should consult the full paper for detailed quantitative results and forest plots.
The meta-analysis identified preliminary improvements in insulin resistance measured by HOMA-IR. This effect was based on data from two included studies, so evidence for improvement in insulin resistance is described as preliminary within the review.
Because only two trials contributed data for HOMA-IR, the authors caution that conclusions regarding metabolic benefits require further confirmation in larger or more numerous RCTs.
The pooled findings demonstrated improvements in total testosterone levels and reductions in clinical hirsutism among women receiving MBIs, suggesting beneficial effects on hyperandrogenism in PCOS. These endocrine changes were highlighted alongside anthropometric and metabolic outcomes, supporting a potential role for MBIs as modulators of endocrine function.
Again, exact numeric changes and statistical parameters are provided in the full manuscript rather than the abstract.
The review examined generic measures of depression and anxiety and found no significant differences between MBI and control groups in pooled analyses of those generic symptom scores.
However, disease-specific quality of life—measures tailored to PCOS-related functioning and symptoms—improved significantly with MBIs. This divergence suggests MBIs may exert meaningful, condition-specific impacts on patient-reported quality of life even when standardized generic mood scales do not register change.
The authors conclude that MBIs show potential as metabolic and endocrine modulators for women with PCOS. The aggregated RCT evidence supports benefits in weight management (BMI, weight, abdominal circumference), preliminary improvements in insulin sensitivity (HOMA-IR from two studies), and reductions in markers of hyperandrogenism (total testosterone and clinical hirsutism).
The review emphasizes that MBIs may offer benefits beyond stress reduction alone, potentially affecting physiological pathways relevant to PCOS. Clinicians and researchers may consider MBIs as adjunctive interventions for PCOS, with attention to individual patient needs and available evidence.
Key limitations reported or implied by the abstract include limited data for some endpoints (for example, HOMA-IR was informed by only two studies) and the absence of significant change in generic depression and anxiety measures despite improvements in disease-specific quality of life.
The abstract does not provide trial-level details such as intervention dosing, adherence, or risk-of-bias breakdowns; these elements are necessary for a granular appraisal and are available in the full text. The total pooled sample size across 10 RCTs was 356 participants, which may limit precision for some outcomes.
For clinicians and guideline developers, the review suggests promising signals for mindfulness-based interventions in PCOS but indicates that further high-quality trials with consistent outcome reporting are needed to strengthen certainty and to define optimal intervention parameters.